A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

LESSONS LEARNED: Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappori, Alberto A., Otterson, Gregory A., Dowlati, Afshin, Traynor, Anne M., Horn, Leora, Owonikoko, Taofeek K., Ross, Helen J., Hann, Christine L., Abu Hejleh, Taher, Nieva, Jorge, Zhao, Xiuhua, Schell, Michael, Sullivan, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/
https://www.ncbi.nlm.nih.gov/pubmed/27694157
http://dx.doi.org/10.1634/theoncologist.2016-0220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/
https://www.ncbi.nlm.nih.gov/pubmed/27694157
http://dx.doi.org/10.1634/theoncologist.2016-0220

Ejemplares similares